Balaji Amines Reports Strong Q1FY27 Results; Highlights Commissioning of India's First Commercial-Scale DME Plant

Balaji Amines Reports Strong Q1FY27 Results; Highlights Commissioning of India's First Commercial-Scale DME Plant​

Solapur, July 27, 2026: Balaji Amines Limited, a leading manufacturer specializing in Aliphatic Amines and Specialty Chemicals in India, announced its unaudited financial results for the quarter ended June 30, 2026. The company reported consolidated revenue of ₹461 crore, EBITDA of ₹121 crore, and net profit of ₹78 crore for Q1FY27.

The performance highlights were driven by stable operations and strategic project execution across the company's diverse portfolio, which includes Methyl Amines, Ethyl Amines, Derivatives of Amines, and various Specialty Chemicals.

Key Financial Performance (₹ Cr.)​

The financial results provided a comparative view across standalone and consolidated figures for Q1FY27 against preceding quarters:

Operational Highlights and Growth Trajectory​

Consolidated Revenue for Q1FY27 stood at ₹461 crore, showing stable operational performance compared to the previous quarter. Total volumes were maintained at 21,587 MT in Q1 FY27, against 27,570 MT recorded in Q1 FY26.

The company achieved a significant milestone by successfully commissioning its 100,000 TPA Dimethyl Ether (DME) plant, noted as India's first commercial-scale DME manufacturing facility. This project strategically positions Balaji Amines into alternate fuel applications, catering to LPG blending and aerosol propellant markets while reinforcing the company’s portfolio of new-age chemicals.

The specialty chemicals division is also progressing rapidly. Balaji Speciality Chemicals Limited is advancing its ₹750 crore phased expansion program, which has been granted Mega Project Status by the Government of Maharashtra under the Package Scheme of Incentives (PSI), 2019. This expansion aims to establish an integrated specialty chemicals platform producing high-value products such as Hydrogen Cyanide (HCN), Sodium Cyanide (NaCN), EDTA, and downstream EDA derivatives like DETA and Piperazine (PIP).

The execution plan includes commissioning the brownfield Unit-I expansion for EDA-based products during FY27. Furthermore, a greenfield facility at MIDC Chincholi is under execution, targeting HCN, NaCN, EDTA, and EDTA-2Na production during FY27.

Management Commentary​

Mr. D. Ram Reddy, Managing Director of Balaji Amines, commented on the results, stating that the company commenced FY27 with a strong financial and operational performance delivered by improved demand across key end-user industries. He noted that the integrated manufacturing platform provides crucial competitive advantages in terms of operational flexibility and cost efficiencies.

The MD highlighted that the successful commissioning of the DME plant is a major step towards diversifying into new-age chemicals and alternate fuel applications, reinforcing commitment to import substitution and long-term value chain creation.

Looking ahead, Mr. Reddy stated confidence in the growth outlook, driven by a healthy order pipeline, improving market demand, ongoing capacity additions, and disciplined execution. The company continues to make steady progress on its expansion pipeline, including projects for N-Methyl Morpholine (NMM) and Acetonitrile (ACN).

BALAMINES Stock Price Movement​

On Monday, Balaji Amines Limited shares rallied, settling at ₹2284.80 after closing up 5.68%. The stock was underpinned by strong trading activity, with a total volume of 323,794 shares recorded during the session.